MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down
Myriad Genetics jumps 21% after Q4 earnings beat estimates by 350% and revenues top forecasts, even as gross margin slips and mental health sales decline.
Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript
Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript
Here's What Key Metrics Tell Us About Myriad (MYGN) Q4 Earnings
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Myriad Genetics (MYGN) Q4 Earnings and Revenues Surpass Estimates
Myriad Genetics (MYGN) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.03 per share a year ago.
Ahead of Myriad (MYGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Myriad (MYGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Should Myriad Genetics Stock Stay in Your Portfolio Right Now?
MYGN shows growth potential from new genetic test launches and a refreshed CCC strategy, but revenue pressure from GeneSight coverage loss remains a drag.
Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
Myriad Genetics (MYGN) Reports Break-Even Earnings for Q3
Myriad Genetics (MYGN) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.06 per share a year ago.
Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth
Myriad Genetics posted Q2 2025 revenue growth of 1% year-over-year, but adjusted for one-time events, growth would have been 5%. Key growth drivers include expanding Hereditary Cancer Testing to unaffected cancer patients and launching the Precise MRD test for molecular residual disease. Full-year 2025 revenue guidance was raised to $818-$828 million, reflecting confidence in continued growth and expanding total addressable markets.
Compared to Estimates, Myriad (MYGN) Q2 Earnings: A Look at Key Metrics
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates
Myriad Genetics (MYGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to earnings of $0.05 per share a year ago.
